Germany expects EU to sign supply deal for BioNTech-Pfizer vaccine soon
Reuters
Published Nov 10, 2020 09:34
Updated Nov 10, 2020 10:01
BERLIN (Reuters) - German Health Minister Jens Spahn expects the European Commision to sign a purchase agreement with BioNTech (O:BNTX) and its partner Pfizer (N:PFE) for its potential vaccine against COVID-19 "in the coming days."
"We will now bring this to a speedy conclusion," Spahn told a news conference in Berlin. "We expect to conclude a contract in the next few days."
The European Commission is in final stage talks with BioNTech-Pfizer over the supply of 200 million doses of their potential COVID-19 shot, with an option to buy another 100 million.
Spahn said he expects Germany will get up to 100 million doses of the BioNTech-Pfizer vaccine.
The companies said on Monday their vaccine was shown to be more than 90% effective, a major victory in the war against a virus that has killed over a million people and battered the world's economy.
Spahn reiterated that he does not expect the vaccine to be available before the first quarter of 2021 but added that he expected it to get approved quickly.
Spahn said news about the vaccine "was a light at the end of the tunnel" and raised the hope that next winter would not be as bad as this one.
He said the European Union was pursuing an extraordinary rolling review process meant to speed up approval of the shot, but stressed that this did not mean that standards would be lowered.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.